Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only ...

Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...

Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...

The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...

In the 132-patient ROCKstar study, almost three quarters of chronic GVHD patients treated with a daily oral dose of belumosudil (KD025) saw an improvement in symptoms that lasted for at least six ...

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

The FDA has approved Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute GVHD in pediatric patients age 2 months and older.

It's a lost opportunity to promote a healthy gut microbiome, recover from treatment-related microbiota injury, and protect against GVHD," said first author Jenny Paredes, PhD, a staff scientist at ...

FDA gives nod of approval to first derived mesenchymal stromal cell therapy for the treatment of pediatric patients with ...

TRX-103 is under development for the treatment of graft versus host disease (GvHD), Crohn’s disease and unspecified indication. The therapeutic candidate comprises of allogenic Treg-cells which are ...

The US Food and Drug Administration (FDA) has approved remestemcel-L (Ryoncil, Mesoblast Ltd), an allogeneic bone marrow‒derived mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...

Mesoblast (ASX:MSB) has received approval from the US Food and Drug Administration (FDA) for Ryoncil (remestemcel-L), making ...